Ruoxi Hong

5PUBLICATIONS
16CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursCancer geneticsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|May 03, 2025
Harnessing the FGFR2/NF2/YAP signaling-dependent necroptosis to develop an FGFR2/IL-8 dual blockade therapeutic strategy.

Dongshao Chen, Zitong Zhao, Ruoxi Hong

|Jan 02, 2025
Metronomic Capecitabine Plus Aromatase Inhibitor as Initial Therapy in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: The Phase III MECCA Trial.

Ruo-Xi Hong, Fei Xu, Wen Xia

|Jun 13, 2024
Pyrotinib and trastuzumab plus palbociclib and fulvestrant in HR+/HER2+ breast cancer patients with brain metastasis.

Dongshao Chen, Fei Xu, Yongkui Lu

|May 05, 2024
Multi-omics portrait of ductal carcinoma in situ in young women.

Ruoxi Hong, Boyang Cao, Dongshao Chen

|Oct 05, 2019
Tumor stromal type is associated with stromal PD-L1 expression and predicts outcomes in breast cancer.

Qinglian Zhai, Jiawen Fan, Qiulian Lin

Pageof 1

Frequent Collaborators

2 joint publications

Fei Xu

2 joint publications

Shusen Wang

1 joint publications

Zitong Zhao

1 joint publications

Yan Wang